BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases.
The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis, and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information.
The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.